Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial

Conclusions:
PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.

Source: Multiple Sclerosis - February 1, 2016 Category: Neurology Authors: Hupperts, R., Lycke, J., Short, C., Gasperini, C., McNeill, M., Medori, R., Tofil-Kaluza, A., Hovenden, M., Mehta, L. R., Elkins, J. Tags: Original Research Papers Source Type: research